Real-Time In Situ Imaging of Immunotherapy Efficacy: A DNA Nanowire-Based Biosensor for Granzyme A-Mediated APE1 Inactivation
- 14 September 2026
- journal article
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 11 (9) , 8617-8628
Abstract
Real-time monitoring of natural killer (NK) cell-mediated cancer immunotherapy efficacy at the cellular and organismal levels remains a critical challenge, primarily due to the ultra-low abundance of Granzyme A (GzmA) delivered into target cells, its rapid spatiotemporal dynamics, and the scarcity of suitable in situ imaging probes. Here, we present a DNA nanowire-based biosensor that leverages a spatially confined catalytic hairpin assembly (SCCHA) system for the real-time in situ imaging of immunotherapy efficacy, achieved by sensing GzmA-induced apurinic/apyrimidinic endonuclease 1 (APE1) inactivation. This biosensor integrates an APE1-responsive molecular beacon (MB) with a spatially organized CHA amplification circuit on a rigid DNA nanowire scaffold. In tumor cells with high endogenous APE1 activity, cleavage of the MB initiates a confined CHA reaction, yielding a strong fluorescence readout. Upon NK cell attack, delivered GzmA specifically inactivates intracellular APE1, thereby suppressing CHA signal amplification and producing a distinct fluorescence attenuation that dynamically visualizes NK cell cytotoxicity. Owing to the spatial confinement effect of the DNA nanowire, the biosensor achieved a 6.44-fold improvement in sensitivity over conventional free-diffusion CHA system. This platform enabled real-time visualization of NK cell−tumor cell interactions, and accurately reported NK cell cytotoxicity through GzmA-mediated APE1 inactivation. In vivo experiments further demonstrated its capability in evaluating immunotherapy efficacy. Collectively, this DNA nanowire-based biosensor provides a highly sensitive and reliable in situ imaging toolkit for evaluating cancer immunotherapy in real time, offering a promising translational approach for preclinical drug screening and personalized immunotherapeutic monitoring.Keywords
Funding Information
- Basic and Applied Basic Research Foundation of Guangdong Province (2026A1515011706)
- Southern Medical University (S202512121200)
- Guangzhou Municipal Science and Technology Program key projects (2024B01J1277)
This publication has 37 references indexed in Scilit:
- Engineering of a Multi‐Modular DNA Nanodevice for Spatioselective Imaging and Evaluation of NK Cell‐Mediated Cancer ImmunotherapyAngewandte Chemie International Edition, 2024
- Fluorogenic Granzyme A Substrates Enable Real‐Time Imaging of Adaptive Immune Cell ActivityAngewandte Chemie International Edition, 2023
- Association of Machine Learning–Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLCJAMA Oncology, 2023
- DNA Nanowire Guided-Catalyzed Hairpin Assembly Nanoprobe for In Situ Profiling of Circulating Extracellular Vesicle-Associated MicroRNAsACS Sensors, 2022
- The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysiseClinicalMedicine, 2021
- Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell CarcinomaJAMA Oncology, 2019
- The Untold Story of Granzymes in Oncoimmunology: Novel Opportunities with Old AcquaintancesTrends in Cancer, 2017
- Mouse granzyme A induces a novel death with writhing morphology that is mechanistically distinct from granzyme B-induced apoptosisCell Death & Differentiation, 2013
- Human AP endonuclease 1 (APE1): From mechanistic insights to druggable target in cancerCancer Treatment Reviews, 2010
- Tumor Suppressor NM23-H1 Is a Granzyme A-Activated DNase during CTL-Mediated Apoptosis, and the Nucleosome Assembly Protein SET Is Its InhibitorCell, 2003